Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis

Evolution, Medicine and Public Health

Volumn 2013, Issue 1, 2013, Pages 65-74

  Borrell, Sònia ^a,b   Teo, Youjin ^a,b   Giardina, Federica ^a,b   Streicher, Elizabeth M ^c   Klopper, Marisa ^c   Feldmann, Julia ^a,b   Müller, Borna ^a,b,c   Victor, Tommie C ^c   Gagneux, Sebastien ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Antimicrobial; Epidemiology; Infection; Microbiology

Indexed keywords

OFLOXACIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ASSAY; BACTERIAL GENE; BACTERIUM COLONY; BACTERIUM ISOLATE; BIOLOGICAL FUNCTIONS; COMPETITIVE FITNESS ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESISTANT TUBERCULOSIS; EPISTASIS; EVOLUTION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GYRA GENE; IN VITRO STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATIONAL ANALYSIS; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; RPOB GENE; SOUTH AFRICA;

EID: 84892970335     PISSN: None     EISSN: 20506201     Source Type: Journal    
DOI: 10.1093/emph/eot003     Document Type: Article

References (35)

1. Lehner B. Molecular mechanisms of epistasis within and between genes. Trends Genet 2011;27:323-31.
2. Breen MS, Kemena C, Vlasov PK et al. Epistasis as the primary factor in molecular evolution. Nature 2012;490: 535-8.
3. Trindade S, Sousa A, Xavier KB et al. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet 2009;5:e1000578.
4. Ward H, Perron GG, Maclean RC. The cost of multiple drug resistance in Pseudomonas aeruginosa. J Evol Biol 2009;22:997-1003.
5. Björkman J, Hughes D, Andersson DI. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci U S A 1998;95:3949-53.
6. Hall AR, Maclean RC. Epistasis buffers the fitness effects of rifampicin-resistance mutations in Pseudomonas aeruginosa. Evolution 2011;65:2370-9.
7. Gagneux S, Long CD, Small PM et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006;312:1944-6.
8. Shcherbakov D, Akbergenov R, Matt T et al. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010;77: 830-40.
9. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999;2:489-93.
10. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010;8:260-71.
11. Weinreich DM, Watson RA, Chao L. Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution 2005;59:1165-74.
12. Muller B, Borrell S, Rose G et al. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2013;29:160-9.
13. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB). Global Report on Surveillance and Response. World Health Organization: Geneva, 2010.
14. Sandgren A, Strong M, Muthukrishnan P et al. Tuberculosis drug resistance mutation database. PLoS Med 2009;6:e1000002.
15. Perdigão J, Macedo R, Silva C et al. From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition. J Antimicrob Chemother 2013;68:27-33.
16. Sun G, Luo T, Yang C et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis 2012;206: 1724-33.
17. World Health Organization. (2012) Global tuberculosis control: surveillance, planning, financing. World Health Organization: Geneva, 2012.
18. Van Der Zanden AGM, Te Koppele-Vije EM, Vijaya Bhanu N et al. Use of DNA extracts from Ziehl-Neelsen-stained slides for molecular detection of rifampin resistance and spoligotyping of Mycobacterium tuberculosis. J Clin Microbiol 2003;41:1101-8.
19. Streicher EM, Bergval I, Dheda K et al. Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrob Agents Chemother 2012;56:2420-7.
20. Maruri F, Sterling TR, Kaiga AW et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012;67: 819-31.
21. Hall AR, Iles JC, MacLean RC. The fitness cost of rifampicin resistance in Pseudomonas aeruginosa depends on demand for RNA polymerase. Genetics 2011;187:817-22.
22. Lalić J, Elena SF. Magnitude and sign epistasis among deleterious mutations in a positive-sense plant RNA virus. Heredity (Edinb) 2012;109:71-7.
23. Wilke CO, Adami C. Interaction between directional epistasis and average mutational effects. Proc Biol Sci 2001; 268:1469-74.
24. O'Sullivan DM, McHugh TD, Gillespie SH. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? J Antimicrob Chemother 2005;55: 674-9.
25. Reece RJ, Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol 1991;26:335-75.
26. Miller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:805-11.
27. McClure WR, Cech CL. On the mechanism of rifampicin inhibition of RNA synthesis. J BiolChem1978;253:8949-56.
28. Almeida Da Silva PEA, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011;66:1417-30.
29. Gupta R, China A, Manjunatha UH et al. A complex of DNA gyrase and RNA polymerase fosters transcription in Mycobacterium smegmatis. Biochem Biophys Res Commun 2006;343:1141-5.
30. Miskinyte M, Gordo I. Increased survival of antibiotic-resistant Escherichia coli inside macrophages. Antimicrob Agents Chemother 2013;57:189-95.
31. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3: 432-42.
32. Zumla A, Hafner R, Lienhardt C et al. Advancing the development of tuberculosis therapy. Nat Rev Drug Discov 2012; 11:171-2.
33. Luo N, Pereira S, Sahin O et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci U S A 2005;102:541-6.
34. Ysern P, Clerch B, Castańo M et al. Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 1990;5: 63-6.
35. Ma Z, Lienhardt C, McIlleron H et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375:2100-9.